Detection of tumour lymphovascular space invasion using dual cytokeratin and CD31 immunohistochemistry

被引:42
作者
Alexander-Sefre, F [1 ]
Singh, N
Ayhan, A
Salveson, HB
Wilbanks, G
Jacobs, IJ
机构
[1] St Bartholomews & London Sch Med, Gynaecol Canc Res Ctr, London EC1M 6BQ, England
[2] St Bartholomews & London Sch Med, Dept Pathol, London EC1M 6BQ, England
[3] Univ Bergen, Gade Inst, Dept Obstet & Gynaecol & Pathol, N-5021 Bergen, Norway
[4] Univ S Florida, Dept Obstet & Gynaecol & Pathol, Tampa, FL 33612 USA
关键词
D O I
10.1136/jcp.56.10.786
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Lymphovascular space invasion (LVSI) is an important step in the complex process of tumour metastasis. Various methods have been used in the past to improve the histological detection of LVSI. Aims: To develop a sensitive immunohistochemical method for the detection of LVSI. Methods: Paraffin wax blocks from 108 patients who had undergone hysterectomy for stage I endometrial cancer were retrieved. Dual immunostaining for pancytokeratin and the CD31 endothelial cell marker was carried out on 4 mum sections cut from these bocks and compared with conventional haematoxylin and eosin staining. Results: The detection rate for LVSI increased threefold compared with conventional haematoxylin and eosin staining in the test group. Conclusion: This finding suggests that LVSI is a much more common phenomenon than previously thought and questions current understanding of tumour metastasis.
引用
收藏
页码:786 / 788
页数:3
相关论文
共 12 条
  • [1] Birner P, 2001, CLIN CANCER RES, V7, P93
  • [2] Comerci G, 1998, INT J GYNECOL CANCER, V8, P23
  • [3] LYMPHVASCULAR SPACE INVOLVEMENT - A PROGNOSTIC INDICATOR IN ENDOMETRIAL ADENOCARCINOMA
    GAL, D
    RECIO, FO
    ZAMUROVIC, D
    TANCER, ML
    [J]. GYNECOLOGIC ONCOLOGY, 1991, 42 (02) : 142 - 145
  • [4] Inoue Y, 1996, CANCER-AM CANCER SOC, V78, P1447, DOI 10.1002/(SICI)1097-0142(19961001)78:7<1447::AID-CNCR11>3.0.CO
  • [5] 2-#
  • [6] Obermair A, 1998, CANCER-AM CANCER SOC, V82, P689, DOI 10.1002/(SICI)1097-0142(19980215)82:4<689::AID-CNCR11>3.3.CO
  • [7] 2-M
  • [8] PALADINI D, 1994, CANCER-AM CANCER SOC, V74, P2491, DOI 10.1002/1097-0142(19941101)74:9<2491::AID-CNCR2820740916>3.0.CO
  • [9] 2-5
  • [10] Schoppmann SF, 2001, ANTICANCER RES, V21, P2351